PharmaSonics' ultrasound success against restenosis
This article was originally published in Clinica
Executive Summary
PharmaSonics is set to continue the phase II/III trial of its Intravascular Sonotherapy (IST) for preventing stent restenosis. The US FDA gave the go-ahead to proceed based on positive results from its phase I feasibility SILENT (Sonotherapy for In-Lesion Elimination of Neointimal Tissue) study.